The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP.
Tomono Kawase
No relevant relationships to disclose
Hiroshi Imamura
Honoraria - Taiho Pharmaceutical
Masahiro Gotoh
No relevant relationships to disclose
Yutaka Kimura
Honoraria - Taiho Pharmaceutical
Shugo Ueda
No relevant relationships to disclose
Jin Matsuyama
No relevant relationships to disclose
Kazuhiro Nishikawa
No relevant relationships to disclose
Naotoshi Sugimoto
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Junya Fujita
No relevant relationships to disclose
Takao Tamura
No relevant relationships to disclose
Norimasa Fukushima
No relevant relationships to disclose
Ryohei Kawabata
Honoraria - Taiho Pharmaceutical
Yukinori Kurokawa
Honoraria - Taiho Pharmaceutical
Toshio Shimokawa
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Toshimasa Tsujinaka
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose